# A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

> **NCT02180789** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 100 (actual)

## Conditions studied

- Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

## Interventions

- **DRUG:** Tamsulosin OCAS

## Key facts

- **NCT ID:** NCT02180789
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180789, "A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02180789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*